Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Alexion Pharmaceuticals ( ALXN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1%. By the end of trading, Alexion Pharmaceuticals fell $1.05 (-1.1%) to $94.11 on average volume. Throughout the day, 995,298 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock ranged in price between $93.82-$95.58 after having opened the day at $95.42 as compared to the previous trading day's close of $95.16. Other companies within the Drugs industry that declined today were: Chelsea Therapeutics International ( CHTP), down 36.4%, Anika Therapeutics ( ANIK), down 21.2%, Alexza Pharmaceuticals ( ALXA), down 11.6%, and Biostar Pharmaceuticals ( BSPM), down 11%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Alexion Pharmaceuticals has a market cap of $18.49 billion and is part of the health care sector. The company has a P/E ratio of 84.2, above the S&P 500 P/E ratio of 17.7. Shares are up 33.1% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Novogen ( NVGN), up 20.3%, Cyclacel Pharmaceuticals ( CYCC), up 19.1%, ARCA biopharma ( ABIO), up 14.8%, and Corcept Therapeutics ( CORT), up 9.3%, were all gainers within the drugs industry with Pfizer ( PFE) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.